SABCS 2022 Conference Coverage
Playback speed
10 seconds
SABCS 2022 Updated Survival Results of the Randomized Phase 3 Study DESTINY-Breast03: T-DXd vs. Trastuzumab Emtansine in Patients With HER2+ mBC
By
SABCS 2022 Conference Coverage
FEATURING
Sara A. Hurvitz
By
SABCS 2022 Conference Coverage
FEATURING
Sara A. Hurvitz
259 views
December 14, 2022
Comments 0
Login to view comments.
Click here to Login
Videos